Recent briefings through early June 2026 did not identify discrete Pfizer-specific corporate news events. The broader macro environment was marked by US-Iran tensions following reports of intercepted Iranian missiles aimed at American forces in Kuwait, which introduced uncertainty into energy and equity markets, with oil trading above $90 per barrel [Brief - 2026-06-01]. No Pfizer earnings announcements, regulatory decisions, or M&A disclosures were cited in the briefings covering the 30-day window preceding this report's generation date.
Pfizer's trailing twelve-month revenue stood at $63.32 billion as of the most recent filing period, representing year-over-year growth of 5.37%. Net income for the same period was $7.49 billion, with a net margin of 11.83% and an operating margin of 35.40%. Earnings per share declined 9.62% year-over-year. The company held $1.70 billion in cash against total debt of $64.46 billion. The price-to-earnings ratio was recorded at 19.56 [SEC 10-Q - PFE - 2026-03-29].
Institutional ownership data from the most recent 13F filings reflects divergent positioning among major allocators. Citadel reduced its PFE position by 17% [SEC 13F - Citadel - Q1 2026]. AQR Capital added 21% to its existing position [SEC 13F - AQR Capital - Q1 2026], while Millennium increased its holding by 9.9% [SEC 13F - Millennium - Q1 2026]. No insider transaction data from SEC Form 4 filings was included in the provided context for this reporting period.
The US 10-year Treasury yield stood at 4.55% and the 2-year yield at 4.17%, producing a normal yield curve spread of approximately 38 basis points [FRED DGS10] [FRED DGS2]. This rate environment is relevant context for a company carrying $64.46 billion in total debt, as prevailing borrowing costs affect refinancing conditions across the broader pharmaceutical sector.
This report was generated in response to material institutional position changes in PFE as reflected in the Q1 2026 13F filings, specifically the concurrent divergence in direction among three significant institutional filers.